

## Supplementary Methods

### *Cell Culture*

MCF10A, MCF10CA1a, MCF10CA1a.c11 and MCF10CA1d.c11 cells were cultured in DMEM/F12 supplemented with 10% horse serum, 20 ng/ml EGF, 10 µg/ml insulin, 0.5 µg/ml hydrocortisone, 100 ng/ml cholera toxin, 100 IU/ml penicillin, and 100 µg/ml streptomycin. MCF-7, T47D, MDA-MB-453, CAMA-1, SKBR3, BT-549 and MDA-MB-231 cells were cultured in DMEM, MDA-MB-436 and MDA-MB-468 in DMEM/F12, and ZR-75-30 in RPMI all containing 10% FBS, 100 IU/ml penicillin, and 100 µg/ml streptomycin. SUMPE44 cells were cultured in serum-free Ham's F-12 supplemented with 5 µg/ml insulin and 1µg/ml hydrocortisone. SUM149PT were cultured in the same medium as SUMPE44 cells supplemented with 5% FCS.

### *Plasmids*

The pUHG10-3(FER) vector (kindly provided by N. Heisterkamp) was used as a template to amplify the full-length human FER cDNA by PCR and subclone it into the pcDNA5/FRT vector (Invitrogen), modified to contain the EF1 $\alpha$  instead of CMV promoter. The EF1 $\alpha$ -FER cassette was amplified by PCR thereby adding a C-terminal V5 epitope tag to the wild-type FER cDNA and flanking *BstBI/XhoI* restriction sites. EF1 $\alpha$ -FER-V5 was then cloned in the *ClaI/XhoI* sites of pLV/CMV to generate pLV/EF1 $\alpha$ -FER-V5 (WT FER). The QuikChange II XL Site-Directed Mutagenesis Kit (200521; Stratagene) was used to generate kinase dead (D742R) FER (D742D FER).

Control and FER-targeting oligonucleotides were annealed and cloned into the FH1tUTG vector. Oligonucleotide sequences were as follows (targeting sequences are capitalized):

control sense:

5'-tcccTTCTCCGAACGTGTCACGTtccaagagaACGTGACACGTTCCGGAGAAtttttc-3'

control anti-sense:

5'-tcgagaaaaTTCTCCGAACGTGTCACGTtctcttgaaACGTGACACGTTCCGGAGAA-3'

FER[680-698] sense:

5'-tcccGGCTCACCATGATGATTAAAttcaagagaTTAATCATCATGGTGAGCCtttttc-3'

FER[680-698] anti-sense:

5'-tcgagaaaaGGCTCACCATGATGATTAAAtctcttgaaTTAATCATCATGGTGAGCC-3'

FER[978-998] sense:

5'-tcccGTATTATGATATCACACTTCCtccaagagaGGAAGTGTGATATCATAATACTtttttc-3'

FER[978-998] anti-sense:

5'-tcgagaaaa GTATTATGATATCACACTTCCtctcttgaaGGAAGTGTGATATCATAATACT-3'

### ***Immunofluorescence analysis***

Primary antibodies used were: rat anti-human CD49f (555734, BD Pharmingen) 1:300, rat anti-integrin  $\beta_1$  (AIIB2, Developmental Studies Hybridoma Bank, The University of Iowa, Iowa City, USA) 1:200, rabbit anti-paxillin pY<sup>118</sup> (44-722; Invitrogen) 1:500. Secondary antibodies were: Alexa Fluor 488 goat anti-rat IgG (A11006) and Alexa Fluor 555 goat anti-rabbit IgG (A21429, Invitrogen) 1:1000. F-actin was visualized with Alexa Fluor 633-conjugated phalloidin (A22284; Invitrogen) 1:200.

### ***Integrin expression measurement***

The following primary antibodies and dilutions were used: mouse anti- $\alpha_2$  integrin (clone 10G11; 1:100), mouse anti- $\alpha_3$  integrin (clone J143; 1:2), mouse anti- $\alpha_v$  integrin (clone 13C2; 1:10), rat anti- $\beta_1$  integrin (clone A11B2; 1:200), rat anti- $\alpha_5$  integrin (clone M16; 1:1000), rat anti- $\alpha_6$  integrin (555734, BD Pharmingen; 1:100). The secondary antibodies and dilutions used were: Alexa Fluor 488 goat anti-mouse IgG (A11001, Invitrogen; 1:500), Alexa Fluor 488 goat anti-rat IgG (A11006, Invitrogen, 1:500).